New adjuvants: EU regulatory developments

被引：17
|
作者：
Sesordic, Dorothea
Rijpkemo, Sjoerd
Patel, Brijesh Prokosh
机构：
[1] Natl Inst Biol Stand & Controls, Div Bacteriol Blanche Lane, Potters Bar EN6 3QG, Herts, England
[2] Med & Healthcare Prod Regulatory Agcy, Biol Biotechnol Unit, London SW8 5NQ, England
来源：
EXPERT REVIEW OF VACCINES | 2007年 / 6卷 / 05期
关键词：
adjuvant; clinical evaluation; human vaccine; nonclinical safety evaluation; quality/pharmaceutical evaluation; regulatory development; regulatory requirements;
D O I：
10.1586/14760584.6.5.849
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
This paper discusses EU regulatory texts that are relevant for the introduction of new adjuvants in human vaccines and discusses the EU requirements at the developmental level, during the manufacturing process and at the final product stage. The emphasis is on regulatory expectations regarding safety at preclinical and clinical stages. The article highlights regulatory concerns and existing bottlenecks that have led to a slow approval process for new adjuvants.
引用
收藏
页码：849 / 861
页数：13
相关论文
共 40 条
  • [31] Quality and Regulatory Requirements for the Manufacture of Master Cell Banks of Clinical Grade iPSCs: The EU and USA Perspectives
    Martins, Fernando
    Ribeiro, Maria H. L.
    STEM CELL REVIEWS AND REPORTS, 2025, : 645 - 679
  • [32] Use of new adjuvants in an emergency vaccine against foot-and-mouth disease virus: Evaluation of conferred immunity
    Quattrocchi, V
    Bianco, V
    Fondevila, N
    Pappalardo, S
    Sadir, A
    Zamorano, P
    CONTROL OF INFECTIOUS ANIMAL DISEASES BY VACCINATION, 2004, 119 : 481 - 497
  • [33] Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice
    Favoino, E.
    Favia, E. I.
    Digiglio, L.
    Racanelli, V.
    Shoenfeld, Y.
    Perosa, F.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (01): : 32 - 40
  • [34] Stress-Testing Liquidity Risks in the New Regulatory Environment
    Schmitt, Eugenia
    PROCEEDINGS OF THE 9TH INTERNATIONAL CONFERENCE ON CURRENCY, BANKING AND INTERNATIONAL FINANCE, 2017, : 232 - 239
  • [35] Pharmaceutical treatment of advanced urinary bladder cancer. New developments in 2014
    Schmid, S. C.
    Gschwend, J. E.
    Retz, M.
    UROLOGE, 2014, 53 (10): : 1535 - 1541
  • [36] New developments in cosmetic applications of electromagnetic fields: Client and occupational hazard assessment
    Stam, Rianne
    BIOELECTROMAGNETICS, 2024, 45 (06) : 251 - 259
  • [37] COMPARISON OF THE EFFECTS OF ADJUVANTS AND ADJUVANT DOSES ON THE QUANTITATIVE AND QUALITATIVE ANTIBODY-RESPONSE TO SELECTED ANTIGENS IN NEW-WORLD SQUIRREL-MONKEYS SAIMIRI-SCIUREUS
    PERRAUT, R
    HUNDT, E
    GARRAUD, O
    ENDERS, B
    GYSIN, J
    VACCINE, 1993, 11 (07) : 730 - 736
  • [38] Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria
    Alijotas-Reig, J.
    LUPUS, 2015, 24 (10) : 1012 - 1018
  • [39] Ethical governance of the medical research: clinical investigation and informed consent under the new EU Medical Devices Regulation (2017/745)
    Olimid, Daniel-Alin
    Olimid, Anca Parmena
    Chen, Feng Ifrim
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (04): : 1305 - 1310
  • [40] The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants
    Chen, Lei
    Xu, Miao
    Wang, Zhi-Yu
    Chen, Bao-Wen
    Du, Wei-Xin
    Su, Cheng
    Shen, Xiao-Bing
    Zhao, Ai-Hua
    Dong, Na
    Wang, Ya-Jun
    Wang, Guo-Zhi
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2010, 59 (01): : 42 - 52
1234